Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study

Published:2021-01-01 Issue:1 Volume:23 Page:41-50
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Bode Bruce W.¹,Garg Satish K.²,Norwood Paul³,Morales Cristobal⁴,Hardy Thomas⁵,Liu Rong⁵,Ignaut Debra⁵

Affiliation:

1. Department of Endocrinology, Atlanta Diabetes Associates, Atlanta, Georgia, USA.

2. Department of Endocrinology, Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, USA.

3. Department of Endocrinology, Valley Research, Fresno, California, USA.

4. Department of Endocrinology, Hospital Universitario Virgen Macarena, Seville, Spain.

5. TH and DI Medical Development, RL Clinical Design, Delivery, and Analytics, Eli Lilly and Company, Indianapolis, Indiana, USA.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2020.0224

Reference13 articles.

1. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

2. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation

3. Ultrafast-Acting Insulins: State of the Art

4. 1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

5. 1107-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T1D

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes;Diabetes Technology & Therapeutics;2024-09-01

2. Analogues ultra-rapides de l’insuline et délivrance automatisée de l’insuline, un réel pas en avant ?;Médecine des Maladies Métaboliques;2024-06

3. The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus;Journal of Diabetes Science and Technology;2023-11-08

4. Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2023-11

5. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion;Diabetes, Obesity and Metabolism;2023-10-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3